1	Covid-19 Vaccination in Pregnancy: A Systematic Review
2	Nando Reza Pratama ¹ , Ifan Ali Wafa ¹ , David Setyo Budi ¹ , Manesha Putra ² , Manggala Pasca
3	Wardhana ^{3,4} Citrawati Dyah Kencono Wungu ^{5,6,*}
4	
5	¹ Faculty of Medicine, Universitas Airlangga, Indonesia
6	² Department of Obstetrics and Gynecology, University of Colorado Anschutz School of
7	Medicine, Aurora, United States
, 8	³ Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga.
9	Indonesia
10	⁴ Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
11	⁵ Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas
12	Airlangga, Indonesia
13	⁶ Institute of Tropical Disease, Universitas Airlangga, Indonesia
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	Correspondence:
30	Citrawati Dyah Kencono Wungu, MD., PhD.
31	Department of Physiology and Medical Biochemistry, Airlangga University
32	Jalan Mayjen Prof. Dr. Moestopo No.47, Surabaya, Indonesia
33	Email: <u>citrawati.dyah@fk.unair.ac.id</u>

34 Abstract

35 Objective: Pregnancy is a risk factor for severe Covid-19. Looking for safe vaccines that
36 evoke protective maternal and fetal antibody response is important.

Methods: We searched from registries (ClinicalTrials.gov, the WHO Clinical Trial 37 38 Registry, and the EU Clinical Trial Registry) and databases (MEDLINE, 39 ScienceDirect, Cochrane Library, Proquest, and Springer) up until June 20, 40 2021. Articles were selected based on inclusion and exclusion criteria after 41 duplicates were removed. Infection rate, maternal antibody response, placental 42 antibody transfer, and adverse events were described. This systematic review 43 was performed with quality assessment and semi-quantitative synthesis 44 according to PRISMA guidelines.

45 **Results**: Twelve observational studies with a total of 40.509 pregnant women included. 46 The mRNA based vaccines (Pfizer-BioNTech and Moderna) can prevent 47 future SARS-CoV-2 infections (p=0.0004). Both vaccines did not affect 48 pregnancy, delivery, and neonatal outcomes. The most commonly encountered 49 adverse reactions are injection-site pain, fatigue, and headache but only 50 transient. Antibody responses were rapid after the prime dose of vaccines. 51 After booster, antibody responses were higher and associated with better 52 placental antibody transfer. Longer intervals between first vaccination dose and delivery were also associated with higher antibody fetal IgG and better 53 54 antibody transfer ratio.

55 Conclusions: The Pfizer-BioNTech and Moderna vaccines are efficacious for preventing
56 future SARS-CoV-2 infections. These vaccines can be considered as a safe
57 option for pregnancy and their fetus. Two doses of vaccines were
58 recommended for more robust maternal and fetal antibody responses. Longer
59 latency was associated with higher fetal antibody responses.

60 Keywords: Covid-19; Pregnancy; Vaccine; Antibody; Neonate

61 Systematic Review Registration: PROSPERO (CRD42021261684)

62

- 63
- 64

65

66 INTRODUCTION

67 The impact of coronavirus disease 2019 (Covid-19) on pregnancy remains unclear 68 due to insufficient information, while most available studies have evaluated the impact of the 69 disease only in the general population. The risk of severe Covid-19 in pregnancy appears to 70 be no greater than for the general population; pregnant women are at a higher risk for 71 acquiring viral respiratory infections and severe pneumonia due to the unique physiological changes in their immune and cardiopulmonary systems.^{1,2} Although most pregnant women 72 73 had mild to moderate symptoms only, SARS-CoV-2 infection is found more severe in 74 pregnant women than their nonpregnant counterparts, with an increased risk of hospital admission, intensive care unit stay, and death.³ 75

Despite their higher risk of SARS-CoV-2 infection, pregnant and lactating women were not included in any initial Covid-19 vaccine trials, resulting in data scarcity to guide vaccine decision making in these populations.⁴ A prior study revealed that most pregnant women with Covid-19 admitted to the hospital were asymptomatic, which allows these undetected patients to transmit the virus to others.^{5,6} This finding shows that efforts to prevent SARS-CoV-2 infection, one of them by vaccination, are critical for investigation on this population.

To facilitate comprehending the Covid-19 vaccine in pregnancy, we performed a systematic review to critically evaluate and summarize the latest evidence of Covid-19 vaccination regarding the efficacy, immunogenicity, and safety profile in the pregnant population.

87 METHODS

This systematic review adhered to PRISMA (Preferred Reporting Items for Systematic
Review and Meta-Analysis) 2020 guidelines⁷ and has been previously registered in the
PROSPERO database (CRD42021261684).

91 Eligibility criteria

92 We accepted any study (retrospective, prospective, cohort, randomized controlled trials 93 (RCT), case series, case control, cross-sectional, crossover) to be included in the review. The 94 authors screened the title and abstract of independently for eligible studies based on the 95 following criteria: (1) pregnant women; (2) adult (≥18 years) female study population; (3) the 96 study involved Covid-19 vaccine of interest; (4) the study compared the intervention group 97 with control (non-pregnant women, unvaccinated, or none); (5) eligible studies should have 98 reported at least one of our outcomes of interest; (6) English language. Our primary outcomes 99 included infection rate, maternal titer antibody, local and systemic adverse events. Our 90 secondary outcomes included neonatal outcome, cord blood titer antibody, and placental 91 transfer ratio. We excluded review articles, irrelevant, non-human studies, and duplications.

102 Search strategy and selection of studies

103 The authors comprehensively conducted keyword searching of articles published in trial 104 registries (ClinicalTrials.gov, the WHO Clinical Trial Registry, and the EU Clinical Trial 105 Registry) and databases (MEDLINE, ScienceDirect, Cochrane Library, Proquest, and 106 Springer) up until June 20, 2021. Our research is limited to studies involving humans with no 107 language restrictions. Manual search, including in BioRxiv and MedRxiv, and the 108 bibliographical search were also conducted to obtain additional evidence. The following 109 keywords were used: "((SARS-CoV-2) OR (COVID-19)) AND ((pregnancy) OR (pregnant)) 110 AND ((vaccine) OR (vaccination))". The search strategies are available in *Supplementary* 111 *Materials*. We exported all studies retrieved from the electronic searches into Mendeley 112 reference manager for removing duplication and screening. The two review authors (NRP 113 and IAW) independently screened the title and abstract of the articles to identify potentially 114 eligible studies and subsequently screened the full texts independently. Any disagreements 115 between the two review authors were resolved by discussion until reaching consensus. 116 Excluded studies were described in the PRISMA flow diagram alongside their reasons for 117 exclusion (Figure 1).

118 Data extraction

The review authors (NRP, IAW, and DSB) independently extracted relevant data using structured and standardized form from each selected study. The following information was extracted: first author's name and publication year, study design, country, sample size, gestational age at first vaccine, sample size, age, sample collection, vaccine type, and outcomes (infection rate, maternal titer antibody, cord blood titer antibody, placental transfer ratio and local and systemic adverse events). Any disagreements between the review authors were consulted with the expert and resolved by discussion until reaching consensus.

126 Quality assessment

Two review authors (IAW and DSB) independently assessed the risk of bias from each included studies using Newcastle-Ottawa Scale (NOS) assessment tool for cohort studies and Joanna Briggs Institute (JBI) critical appraisal checklist for case report, case series, and cross-sectional studies.^{8,9} Newcastle-Ottawa Scale contains eight items within three domains, including patient selection, comparability, and outcomes. A study with scores 7-9, 4-6, and 0-3 were considered to be high, moderate, and low-quality, respectively. Any discrepancies were resolved by discussion until reaching consensus.

134 Statistical analysis

135 Due to important differences in comparison of each study and various outcome measures, we

136 could not generate meta-analyses of the included studies but rather we performed narratively

137 synthesized the evidence using Synthesis Without Meta-analysis (SWiM) reporting guideline

138 (intended to complement the PRISMA guidelines in these cases).

139 **RESULTS**

140 Study selection

141 The search strategy yielded 4112 and 199 records, respectively, from database searching and 142 additional searching, in medRxiv, bioRxiv, and clinicaltrial.gov. After screening the titles and 143 abstracts, 47 potentially eligible articles were reviewed. After the full-text assessment, twelve 144 studies were included in this systematic review. The process of study selection in this review 145 is described in the PRISMA flow diagram (**Figure 1**), along with the reason for exclusion.

146 Quality assessment

Eight cohort studies were assessed using the NOS assessment tool and considered as high
quality since all of the studies scored 7-9 (see *Table S1 in Supplementary Materials*). The
quality assessment of case report, case series, and cross-sectional studies using the JBI
critical appraisal checklist was summarized in Supplementary Materials (Table S2 – S4).

151 Study characteristics

There are twelve observational studies with a total of 40.509 pregnant women who received Covid-19 vaccines included in this systematic review. Among these studies, ten studies (six cohort, one cross-sectional, one case series, and two case report) were conducted in the United States of America (USA) while other two cohort studies were carried out in Israel in 2021. The maternal age ranged from 16 to 54 years. All pregnant women reported receiving mRNA vaccine, either Pfizer–BioNTech or Moderna vaccine, except for four pregnant

women who received unknown types of vaccine.¹⁸ Some studies compared vaccinated 158 159 pregnant women with unvaccinated pregnant women, either naturally infected or not infected, 160 or vaccinated non-pregnant women. The efficacy outcome was desribed as infection rate, 161 while immunogenicity was described as maternal antibody response, fetal antibody response, 162 and transplacental antibody transfer. Safety outcome was described as the adverse events, 163 maternal outcomes, and neonatal outcomes. Adverse events were divided into local and 164 systemic, local adverse events include injection-site pain and soreness, while systemic 165 adverse events include fatigue, headache, myalgia, chills, fever and nausea.




Figure 1 PRISMA flow diagram of study selection process⁷

Table 1A. Characteristics of the included studies

Reference	Study design	Country	Gestational age at first vaccine or 1st vaccine-	Samp	ble size	Mean ± S	ge, y D or Median QR)	Sample collection Vaccine		Outcomes
		country	to- delivery interval dose	Pregnant (N)	Not Pregnant (N)	Pregnant (N)	Not Pregnant (N)		type	
Shimabukuro et al., 2021 ¹⁰	Cohort	United States	NR	Vaccinated 39,870	0	Vaccinated 33 (16-54)	NR	Data from "v-safe and VAERS.	Pfizer– BioNTech and Moderna.	Infection rate, local adverse events, systemic adverse events, pregnancy loss, and neonatal outcomes.
Gray et al., 2021 ¹¹	Cohort	United States	Gestational age at first vaccine (Mean) 23.2 weeks	Vaccinated 84	Non- pregnant, received vaccine: 16	Vaccinated 34.1±3.3	Vaccinated 38.4±8.3	Antibodies in umbilical cord blood, maternal sera, and breastmilk were quantified using ELISA. Adverse events were assessed using questionnaire.	Pfizer– BioNTech and Moderna.	Maternal antibody titer, local adverse events, systemic adverse events, adverse pregnancy outcome, and composite infant morbidity.
Collier et al, 2021 ¹²	Cohort	United States	Gestational age at first vaccine dose (N (%)) <14 week: 5 (17%) 14-28 week: 15 (50%) ≥28 week:	Vaccinated 30 Infected, not vaccinated 22	Neither pregnant nor lactating, received vaccine: 63	Vaccinated 35 (32-36) Not vaccinated: 31 (28-36)	Vaccinated: 30 (25-35) Not vaccinated: 34 (33-38)	SARS-CoV-2 RBD in serum and milk were assessed by ELISA. Neutralizing antibody activity was assessed by Luciferase Assay System.	Pfizer– BioNTech and Moderna.	Maternal antibody titer, systemic adverse events, cord blood antibody titer, and breast milk antibody titer.
Shanes et al, 2021 ¹³	Cohort	United States	10 (33%) 1st vaccine- to-delivery interval (Mean±SD) 45.96±24.3 days	Received vaccine: 84 Neither vaccinated nor infected:	0	Vaccinated 33.7±3.1 Not vaccinated: 32.5±4.8	NR	Antibody testing from plasma used a paramagnetic particle, chemiluminescent immunoassay.	mRNA vaccines.	Maternal antibody titer and placental finding.

				116						
Prabhu et al, 2021 ¹⁴	Cohort	United States	NR	Received vaccine: 122	Neonates: 122	NR	NR	Semi-quantitative testing for RBD used (ET HealthCare) 3 on sera of maternal peripheral blood and neonatal cord blood.	Pfizer– BioNTech and Moderna.	Maternal antibody, Neonatal IgG, Maternal antibody vs neonatal IgG, Placental transfer ratio.
Gill and Jones, 2021 ¹⁵	Case Report	United States	Gestational age at first vaccine dose: 32.9 weeks	Received vaccine: 1	0	34 years	NR	Cord blood and maternal blood .	Pfizer– BioNTech	Maternal antibody, cord blood IgG
Kadali et al, 2021 ¹⁶	Cross- sectional study	United States	NR	Pregnant, received vaccine: 38	Non pregnant, received vaccine: 991	NR	NR	Independent online survey questionnaire (Survey Monkey, San Mateo, CA). Anonymous responses about the side effects were collected from HCWs representing various parts of the country	Pfizer– BioNTech and Moderna.	Local adverse events, and systemic adverse events.
Rottenstreich <i>et al.</i> , 2021 ¹⁷	Cohort	Israel	1st vaccine- to-delivery interval (Median (IQR)) 33 (30-37) days	20	0	32 (28-37) years	NR	Antibody in maternal and cord blood sera were assessed by chemiluminescent microparticle immunoassay (CMIA).	SARS- CoV-2 BNT162b2 mRNA vaccine.	Maternal IgG, cord blood IgG and placental transfer ratio.
Mithal <i>et al.</i> , 2021 ¹⁸	Prospective case series	United States	Gestational age at first vaccine dose (Mean±SD) 33±2 weeks	Received vaccine: 27	Neonates: 28 (1 twin pair)	33±3 years;	NR	Maternal blood and umbilical cord blood using paramagnetic particle, chemiluminescent immunoassay.	Pfizer– BioNTech, Moderna, and unknown.	Maternal antibody titer, positive IgM rate, positive IgG rate, IgG transfer outcomes, and Infant IgG outcomes.
Theiler et al., 2021 ¹⁹	Cohort	United States	Gestational age at first vaccine dose (Median (IQR)) 32 (13.9- 40.6) days	Received vaccine: 140 Had Covid- 19 infection during pregnancy: 212	0	31.8±3.72 years	30.0±5.32 years	Electronic medical record from Mayo Clinic	Pfizer– BioNTech and Moderna.	Infection rate, Maternal and delivery outcome, and length of stay.

Beharier <i>et al.,</i> 2021 ²⁰	Cohort	Israel	Gestational age at first vaccine dose (Mean±SD) 34.5±7.5 weeks	Received vaccine: 92 Neither vaccinated nor infected: 66 Past SARS- CoV 2 infections: 74	0	Vaccinated 31.7±5.8 years Not vaccinated, not infected: 31.6±5.8 years Past SARS- CoV 2 infections: 28.8±5.8 years	NR	Maternal and fetal blood samples Sera IgG and IgM titers were measured using bead- based multiplex assay (for S1, S2, RBD and N).	Pfizer– BioNTech.	Temporal dependence in pregnant women, temporal dependence in neonates, maternal IgG between vaccinated vs PCR- positive, and Maternal-fetal IgG response to infection and vaccination correlation.
Paul and Chad, 2021 ²¹	Case Report	United States	36.4 weeks	Received vaccine: 1	0	NR	NR	The Electro- chemiluminescence Immunoassay (ECLIA) uses a recombinant protein representing the RBD	Moderna.	Cord blood antibody level.

Table 1B. Outcomes of the individual studies

Reference	Infection rate N (%)			-CoV 2 antibody titer or Median (IQR))	Local adverse event N (%)		
Reference	Intervention	Comparison	Pregnant	Non-Pregnant	Pregnant	Non-Pregnant	
Shimabukuro et al., 2021 ¹⁰	Pfizer- BioNTech vaccine ≤14 days after first eligible dose of vaccination: 3 (0.1%) >14 days after first eligible dose of vaccination: 9 (0.4%)	Moderna vaccine ≤14 days after first eligible dose of vaccination: 7 (0.4%) >14 days after first eligible dose of vaccination: 3 (0.2%)	NR	NR	Integration Pfizer-BioNTech vaccine $(1^{st} dose vs 2^{nd} dose)$ Injection-site pain: 7602 (84%) vs 5886 (89%) Injection-site redness: 160 (2%) vs 169 (3%) Injection-side itching: 103 (1%) vs 109 (2%) Moderna vaccine (1 st vs 2 nd dose) Injection-site pain: 7360 (93%) vs 5388 (96%) Injection-site redness: 348 (4%) vs 491 (9%) Injection-side itching: 157 (2%) vs 193 (3%)	NR	
Gray <i>et al.</i> , 2021 ¹¹	NR	NR	NR	NR	First dose vaccine Injection-site soreness: 73 (88%) Injection site reaction or rash: 1 (1%) Second dose vaccine Injection-site soreness: 44 (57%) Injection site reaction or rash: 1 (1%)	First dose vaccine Injection-site soreness: 12 (75%) Injection site reaction or rash: 0 (0%) Second dose vaccine Injection-site soreness: 12 (75%) Injection site reaction or rash: 0 (0%)	
Collier <i>et al.</i> , 2021 ¹²	NR	NR	Vaccinated RBD IgG (median): 27,601 AU Neutralizing Ab (median): 910 AU Infected RBD IgG (median): 1,321 AU Neutralizing Ab (median): 148 AU	Vaccinated RBD IgG (median): 37,839 AU Neutralizing Ab (median): 901 AU Infected RBD IgG (median): 771 AU Neutralizing Ab (median): 193 AU	NR	NR	
Shanes <i>et al.</i> , 2021 ¹³	NR	NR	Vaccinated RBD IgG: 22.8±14.5 RBD IgM: 4.1±13.2 Unvaccinated RBD IgG: 0.04±0.05	NR	NR	NR	

NR NR NR	NR SARS-CoV-2 IgG titer: 1:25600 (+) NR	NR NR	NR NR Sore arm or pain: 37 (97%)	NR NR Sore arm or pain: 894 (90%)
	1:25600 (+)		Sore arm or pain: 37 (97%)	
NR	NR	ND		Sore arm or pain: 894 (90%)
		NR	Itching: 2 (5%) Muscle spasm: 1 (3%)	Itching: 98 (10%) Muscle spasm: 103 (10%)
NR	Anti-S IgG: 319 (211-1033) AU/mL Anti-RBD-Specific IgG: 11,150 (6154-17,575) AU/mL	NR	NR	NR
NR	NR	NR	NR	NR
Not vaccinated: ie: None: (99%) 1652 (89%) nester 1: Trimester 1: 26 1%) (1%) nester 2: Trimester 2: 84 %) (5%) nester 3: Trimester 3: 100 (5%)	NIP	NR	NR	NR
0.0004				
NR	NR	NR	NR	NR
	NR	NR	NR	NR
9%) 0.0004	100 (5%)	100 (5%) NR NR	100 (5%)	100 (5%)

Reference	Systemic adverse	e events N (%)	Others
Kelelelice	Pregnant	Non-Pregnant	Others
	Pfizer-BioNTech vaccine (1 st dose vs 2 nd dose)		Maternal and delivery outcomes
	Fatigue: 2406 (27%) vs 4231 (64%)		Pregnancy loss among complete pregnancy (N (%))
	Headache: 1497 (17%) vs 3138 (47%)		- Abortion: 104 (12.6%)
	Myalgia: 795 (9%) vs 2916 (44%)		- Stillbirth: 1 (0.1%)
	Chills: 254 (3%) vs 1747 (26%)		Neonatal outcome among live-born infants (N (%))
	Fever or felt feverish: 256 (3%) vs 1648 (25%)		- Preterm birth: 60 (9.4%)
	Measured temperature \geq 38°C: 30 (0%) vs 315 (5%)		- Small size for gestational age: 23 (3.2%)
Shimabukuro	Nausea: 492 (5%) vs 1356 (20%)		- Congenital anomalies (N=16; 2.2%)
et al, 2021^{10}	Moderna vaccine (1 st vs 2 nd dose)	NR	- Neonatal death (N=0; 0%)
	Fatigue: 2616 (33%) vs 4541 (81%)		
	Headache: 1581 (20%) vs 3662 (65%)		
	Myalgia: 1167 (15%) vs 3722 (66%)		
	Chills: 442 (6%) vs 2755 (49%)		
	Fever or felt feverish: 453 (6%) vs 2594 (46%)		
	Measured temperature \geq 38°C: 62 (1%) vs 664 (12%)		
	Nausea: 638 (8%) vs 1909 (34%)		
	First dose vaccine	First dose vaccine (N (%))	Adverse pregnancy outcome (N (%))
	Headache: 7 (8%)	Headache: 5 (31%)	Fetal growth restriction: 0 (0%)
	Muscle aches: 2 (2%)	Muscle aches: 2 (12%)	Preeclampsia/gestational hypertension: 0 (0%)
Gray et al,	Fatigue: 12 (14%)	Fatigue: 6 (38%)	Preterm delivery (spontaneous): 1 (8%)
2021 ¹¹	Fever or chills: 1 (1%)	Fever or chills: 1 (6%)	Preterm delivery (medically indicated): 0 (0%)
2021	Second dose vaccine	Second dose vaccine (N (%))	Composite infant morbidity (N (%))
	Headache: 25 (32%)	Headache: 6 (38%)	Supplemental oxygen/CPAP: 1 (8%)
	Muscle aches: 37 (48%)	Muscle aches: 7 (44%)	TTN: 1 (8%)
	Fatigue: 41 (53%)	Fatigue: 9 (56%)	Special care nursery admission: 0 (0%)

Fever or chills: 25 (32%)	Fever or chills: 8 (50%)	NICU admission: 2 (15%)
		Respiratory distress syndrome: 0 (0%)
		Necrotizing enterocolitis: 0 (0%)
		Sepsis: 0 (0%)
		Assisted ventilation: 0 (0%)
		Seizure: 0 (0%)
		Grade 3/4 intraventricular hemorrhage: 0 (0%)
		Death: 0 (0%)
		IgG Spike response
		Pregnant V1 vs Pregnant V0: P<0.0001
		Pregnant V2 vs Pregnant V0: P<0.0001
		Pregnant V2 vs Pregnant V1: P<0.05
		Cord blood IgG titer vs time from maternal V2 corr.(r): 0.8; p=0.01
		Vaccinated pregnant vs natural infection pregnant titer: P<0.0001
		IgG RBD response
		Pregnant V1 vs Pregnant V0: P<0.01
		Pregnant V2 vs Pregnant V0: P<0.0001
		Pregnant V2 vs Pregnant V1: P<0.001
		Cord blood IgG titer vs time from maternal V2 corr.(r): 0.50; p=0.17
		Neutralizing antibody titer (umbilical cord vs maternal serum)
		Medial (IQR): 104 (61.2-188.2) vs 52.3 (11.7-69.6); P=0.05
		Antibodies transfer from maternal to cord blood
		Spike IgG3 (r): 0.93; p=0.03
		RBD IgG3 (r): 0.81; p=0.07

			RBD IgG titer median (mother serum vs cord blood)
			Vaccinated: 14953 vs 19873
			Infected: 1324 vs 635
			Neutralizing antibodies titer median (mother serum vs cord blood)
Collier et al,	Fever after first dose: 0 (0%)	Fever after first dose: 1 (2%)	Vaccinated: 1016 AU vs 324
2021 ¹²	Fever after second dose: 4 (14%)	Fever after second dose: 27 (52%)	Infected: 151 vs 164
2021	rever after second dose. 4 (14%)	rever after second dose. 27 (32%)	RBD IgG against SARS-CoV-2 Variants of Concern
			Binding antibody responses were comparable against wild type USA-
			WA1/2020 and B.1.1.7 RBD proteins in nonpregnant, pregnant, and
			lactating women and in infant cord samples but were lower for the
			B.1.351 RBD protein.
Shanes et al, 2021 ¹³	NR	NR	NR
			Positive maternal antibody rate
			Women with detectable:
			- IgG & IgM (N (%)): 87 (71%)
			- IgG only (N (%)): 19 (16%)
			Women with no detectable IgG & IgM (N (%)): 16 (13%)
Prabhu et al,			Positive neonatal antibody rate
2021 ¹⁴	NR	NR	IgG from whom the mother received:
2021			- One vaccine dose (N (%)): 24 (43.6%)
			- Two vaccine doses (N (%)): 65 (98.5%)
			Placental transfer outcome
			Maternal IgG and neonatal IgG correlation (R): 0.89, p<2.2 e-16
			Placental transfer ratio and weeks elapsed since maternal vaccination
			dose 2 correlation (R): 0.8, p=2.6 e-16
Gill and	NR	NR	Cord blood antibody:
Jones, 2021 ¹⁵			SARS-CoV-2 IgG titer: 1:25600 (+)
Kadali et al.,	Pregnant	Non pregnant	NR

2021 ¹⁶	Fatigue: 22 (58%)	Fatigue: 643 (65%)	
	Headache: 19 (50%)	Headache: 519 (52%)	
	Chills: 18 (47%)	Chills: 424 (43%)	
	Myalgia: 13 (34%)	Myalgia: 488 (49%)	
	Nausea: 11 (29%)	Nausea: 211 (21%)	
	Fever: 6 (16%)	Fever: 279 (28%)	
	Seizure*: 1 (3%)	Seizure*: 0 (0%)	
			Cord-Blood level
			Anti-S IgG (median (IQR)): 193 (111-260) AU/mL
Rottenstreich	ND	NR	Anti-RBD-specific IgG (median (IQR)): 3494 (1817-6163) AU/mL
<i>et al.</i> , 2021 ¹⁷	NR	INK	Placental transfer ratio
			Anti-S IgG (median (IQR)): 0.44 (0.25-0.61)
			Anti-RBD-specific IgG (median (IQR)): 0.34 (0.27-0.56)
			Positive IgM rate
			Maternal serum (N (%)): 15 (56%)
			Cord blood (N (%)): 0 (0%)
			Positive IgG rate
			Maternal serum (N (%)): 26 (96%)
			Cord blood (N (%)): 25 (89%)
Mithal et al.,			IgG transfer outcomes
2021 ¹⁸	NR	NR	Maternal to infant (mean±SD): 1.0±0.6
2021			Latency from vaccination to delivery vs IgG transfer ratio correlation
			(β): 0.2 (95%CI 0.1-0.2)
			Infant IgG outcomes
			Having received the 2 nd vaccine dose vs infant IgG level correlation
			(β): 19.0 (95% CI 7.1-30.8)
			Latency from vaccination to delivery vs infant IgG level correlation
			(β): 2.9 (95%CI 0.7-5.1)
Theiler et al.,	NR	NR	Maternal and delivery outcome N (%) (vaccinated vs

021 ¹⁹	unvaccinated)
	Adverse outcomes index (AOI): 91 (5%) vs 7 (5%); p= 0.9524
	AOI excluding laceration: 55 (3%) vs 5 (4%); p= 0.6071
	Hypoxic, ischaemic encephalopathy: 1 (0%) vs 0 (0%); p= 1
	Uterine rupture, AOI: 1 (0%) vs 0 (0%); p= 1
	Unplanned ICU admission: 2 (0%) vs 1 (1%); p= 0.1956
	Birth trauma: 11 (1%) vs 0 (0%); p= 1
	Return to OR: 6 (0%) vs 1 (1%); p=0.3985
	NICU admit > 2500g: 11 (1%) vs 1 (1%); p= 0.5821
	5 Minute apgar <7: 38 (2%) vs 3 (2%); p= 0.7617
	Hemorrhage with transfusion: 5 (0%) vs 1 (1%); p= 0.3531
	Third- or fourth-degree laceration: 37 (2%) vs 2 (1%); p= 1
	Mode of delivery: p= 0.6517
	- spontaneous vaginal: 1238 (66%) vs 89 (64%)
	- operative vaginal: 69 (4%) vs 7 (5%)
	- cesarean: 555 (30%) vs 44 (31%)
	Gestational age delivery: p=0.7028
	- 37+: 1703 (91%) vs 127 (91%)
	- 32-36.9: 134 (7%) vs 10 (7%)
	- 24-31.9: 21 (1%) vs 2 (1%)
	- <24: 4 (0%) vs 1 (1%)
	Quantitative blood loss > 1000mL: 56 (3%) vs 6 (4%); p= 0.4452
	Transfusion: 241 (13%) vs 25 (18%); p= 0.1198
	Thromboembolism: 2 (0%) vs 0 (0%); p= 1
	Stroke: 1 (0%) vs 0 (0%); p = 1
	Eclampsia/pre-eclampsia (+/-72 h. of delivery): 23 (1%) vs 1(1%); p=
	Gestational hypertension: 225 (12%) vs 19 (14%); p= 0.6038
	Low birth weight (<2500g): 121 (6%) vs 11 (8%); p= 0.5321
	Very low birth weight (<1500g): 21 (1%) vs 3 (2%); p= 0.2332

		StillBirth: 6 (0%) vs 0 (0%); p= 1
		Temporal dependence in pregnant women
		After infection:
		A gradual rise in IgG humoral response (Anti- S1, S2, RBD and N)
		was detected during the first 45 days after infection.
		After the first dose:
		In the same period, vaccinated participants receiving the first
		BNT162b2 dose showed a rapid IgG response to S1, S2, RBD but no
		N, resulting in high titer values by day 15 after the first dose.
		After the second dose:
		A further rise in IgG was observed following the second dose.
		Temporal dependence in neonates
		After the first dose:
		The temporal dependence of fetal IgG for S1, S2 and RBD after
eharier et NR	NR	vaccination trailed after the maternal IgG showing a significant
<i>l.</i> , 2021 ²⁰	INK	response already by day 15.
		After the second dose:
		A further increase was observed following the second vaccination
		dose.
		Maternal IgG between vaccinated vs PCR-positive
		S1 IgG: higher in vaccination (P=0.0009)
		RBD IgG: higher in vaccination (P=0.0045)
		S2 IgG: higher in PCR-positive (P=0.016)
		N IgG: higher in PCR-positive (P=<0.0001)
		Maternal to fetal IgG transfer ratio for S1, S2, RBD, and N
		PCR-positive vs N^{-} group: Significant differences were found for S1,
		S2 and RBD (P<0.0002)
		PCR-positive vs N^+ group: For all antibodies did not differ (P=0.457)
		Maternal-fetal IgG response to infection and vaccination

			correlation
			S1 IgG: $R^2 = 0.9443$; Adjusted $R^2 = 0.9438$; P<0.0001
			S2 IgG: $R^2 = 0.9353$; Adjusted $R^2 = 0.9348$; P<0.0001
			RBD IgG: R^2 = 0.9200; Adjusted R^2 = 0.9194; P<0.0001
			N IgG: R^2 = 0.9366; Adjusted R^2 = 0.9361; P<0.0001
			Infection vs vaccination maternal-fetal IgG response
			- S1 IgG: P=0.2936
			- S2 IgG: P=0.4212
			- RBD IgG: P=0.0702
			- N IgG: P=0.7616
Paul and			Cord blood Antibody
Chad, 2021 ²¹	NR	NR	IgG concentration: 1.31 U/mL
198 A	bbreviations: NR (not reported); AU (arbitrary unit)		

199 * It reached statistical significance (p=0.0369). However, the participant with a report of seizure has a known history of seizure disorder and her anticonvulsant blood level

200	was	reported	as	borderline	low.
-----	-----	----------	----	------------	------

201 Infection Rate

Among pregnant women who received the Pfizer–BioNTech vaccine, 0.1% (3/2136) of pregnant women experienced Covid-19 infection within 14 days from vaccination and 0.4% (9/2136) after 14 days from vaccination. Additionally, among pregnant women who received Moderna vaccines, 0.4% (7/1822) of pregnant women experienced Covid-19 infection within 14 days from vaccination and 0.2% (3/1822) after 14 days from vaccination.¹⁰ Among unvaccinated vs vaccinated pregnant women, vaccination significantly reduced the risk of future infection (p=0.0004) and all infection cases, reported in the trimester I of vaccinated women, occurred prior to the first vaccination dose.¹⁹

209 Maternal antibody response

Vaccination induced IgG and IgM production in 71% (87/122) pregnant women; 16% (19/122) pregnant women produced only IgG whilst 13% (16/122) had neither detectable IgG nor IgM.¹⁴ Vaccination provided a rapid immunologic response after the first dose while infection provided a gradual immunologic response. Moreover, administration of the second dose can further increase the IgG level among vaccinated women.^{11,20} Spike- and RBD- IgG titer rose rapidly after prime dose (p<0.0001 and p<0.01, respectively); and after receiving booster, it became higher than that of the prime dose (p<0.05 and p<0.001, respectively).¹¹

Vaccination elicited IgG responses against S1, S2, and RBD but not N protein. Meanwhile,
infection elicited all IgG responses against S1, S2, RBD, and N protein. Among vaccinated
pregnant women, S1 IgG and RBD IgG levels were higher (p=0.0009 and p=0.0045, respectively).
Yet, S2 IgG and N IgG were higher in infected pregnant women (p=0.016 and p<0.0001,
respectively).²⁰ Meanwhile, Gray et al., (2021) reported that Spike IgG titer is higher in vaccination
than that of natural infection in pregnant women.¹¹

223 Maternal SARS-CoV-2 spike protein IgG levels between vaccinated and uninfected 224 unvaccinated pregnant women are 22.8±14.5 AU and 0.04±0.05 AU, respectively (p<0.001). While for the IgM levels are 4.1±13.2 AU and 0.19±0.12 AU, respectively (p=0.001).¹³ Among pregnant 225 women that received two vaccine doses, anti-spike-protein IgG concentration median is 319 (211-226 1033) AU/mL and anti-RBD-Specific IgG concentration median is 11150 (6154-17575) AU/mL.¹⁷ 227 Meanwhile, in two women that only received one dose of vaccine, the anti-spike-protein IgG 228 concentrations are 50 AU/mL and 52 AU/m; and the anti-RBD-Specific IgG concentrations are 293 229 AU/mL and 1137 AU/mL.17 230

Antibody response in pregnant and non-pregnant women was evaluated by Collier et al., (2021).¹² The study reported the median of IgG levels between vaccinated and infected pregnant women. The RBD IgG titers were 27601 and 1321, respectively; while the neutralizing antibody titers were 910 and 148, respectively. The median of RBD IgG titers between vaccinated and
 infected non-pregnant women were 37839 and 771, respectively; while for the Neutralizing
 antibody were 901 and 193, respectively.¹²

237 Antibody transfer

A prospective case series reported that the IgG was detected in 89% (25/28) of cord blood, but none had detectable IgM.¹⁸ Moreover, antibody against SARS-CoV-2 RBD and neutralizing antibody was observed in cord blood. On vaccinated women, the maternal vs cord blood RBD IgG was 14953 AU vs 19873 AU, whilst for the neutralizing antibody was 1016 AU vs 324 AU.¹² IgG against S protein was also detected in cord blood with concentration of 193 (111-260) AU/mL and its transfer ratio was 0.44 (0.25-0.61). Furthermore, the concentration of IgG against RBD was 3494 (1817-6163) AU/mL and its transfer ratio was 0.34 (0.27-0.56).¹⁷

Two different case report studies from mother who received two doses of BNT162b2 vaccine and mother who received one dose of Moderna vaccine, respectively, reported that SARS-CoV-2 specific IgG was detected in maternal blood and cord blood at a titer 1:25.600, while cord blood IgG concentration were detected at level of 1.31 U/mL.^{15,21}

Regarding the number of doses received, antibody was detected in 98.5% (65/67) neonates 249 from whom the mother received two doses of vaccine. From mothers who received only one 250 vaccine dose, only 43.6% (24/55) neonates whose antibody was detected.¹⁴ Having received the 251 second vaccine dose was positively correlated with infant IgG level (β =19.0 (95%CI 7.1-30.8)).¹⁸ In 252 addition to doses, the interval from vaccination to delivery was correlated with IgG transfer ratio 253 and infant IgG level. Increased latency from vaccination to delivery was positively correlated with 254 IgG transfer ratio (β =0.2 (95%CI 0.1-0.2)) and infant IgG level (β =2.9 (95%CI 0.7-5.1)).¹⁸ For 255 256 maternal-fetal IgG response, there was no statistical difference between vaccination and SARS-CoV-2 infection for S1 IgG (p=0.2936), S2 IgG (p=0.4212), RBD IgG (p=0.0702), and N IgG 257 (p=0.7616).²⁰ 258

259 Local adverse events

Among pregnant women, injection-site pain is the most common adverse event in both the Pfizer– BioNTech and Moderna vaccines. Following the Pfizer–BioNTech vaccination, as many as 84% (7602/9052) in the first dose and 89% (5886/6638) in the second dose experienced injection-site pain. While for the Moderna vaccine, 93% (7360/7930) and 96% (5388/5635) following the first and the second dose, respectively, experienced injection-site pain.¹⁰ It was also reported 88% (73/84) pregnant women experienced injection-site soreness following the first dose vaccination and 57% (44/84) following the second dose. Additionally, 75% (12/75) non-pregnant women
 experienced injection-site soreness after the first and the second dose of vaccine.¹¹

Between pregnant and non-pregnant women, sore arms or pain were observed in 97% (37/38)
 pregnant women and 90% (894/991) non-pregnant women following Pfizer–BioNTech and
 Moderna vaccination.¹⁶

271 Systemic adverse event

272 Systemic adverse events between two doses of Pfizer-BioNTech and Moderna were reported. Following Pfizer–BioNTech the first vs the second dose of vaccine, six most experienced systemic 273 274 adverse events were fatigue (27% (2406/9052) vs 64% (4231/6638)); headache (17% (1497/9052) vs 47% (3138/6638)), myalgia (9% (795/9052) vs 44% (2916/6638)), chills (3% (254/9052) vs 26% 275 276 (1747/6638)), fever (3% (256/9052) vs 25% (1648/6638)), and nausea (5% (492/9052) vs 20% 277 (1356/6638)). For the Moderna vaccine, fatigue (33% (2616/7930) vs 81% (4541/5635)), headache 278 (20% (1581/7930) vs 65% (3662/5635)), myalgia (15% (1167/7930) vs 66% (3722/5635)), chills (6% (442/7930) vs 49% (2755/5635)), fever (6% (453/7930) vs 46% (2594/5635)), and nausea (8% 279 (638/7930) vs 34% (1909/5635)). Numerically, the incidence of each event is higher in the second 280 dose. Moreover, the Moderna vaccine had more systemic adverse events than that of the Pfizer-281 BioNTech vaccine.¹⁰ Seizure was reported in a woman who received mRNA vaccine (p=0.0369), 282 but it was known that the patient has a history of seizure disorder and the anticonvulsant level in the 283 blood was borderline low.¹⁶ 284

285 Maternal outcomes

- Maternal outcomes were described as pregnancy outcomes and delivery outcomes. Compared to 286 unvaccinated pregnancy, vaccination did not significantly affect pregnancy or delivery outcomes. 287 The adverse outcome index between vaccinated and unvaccinated pregnancy was insignificant 288 (p=0.9524). Between these group, there were no statistical difference in pregnancy outcome such as 289 eclampsia/pre-eclampsia (p=1), gestational hypertension (p=0.6038), gestational age (p=0.7028), 290 and thromboembolism incidence (p=1).¹⁹ Moreover, the abortion rate was reported at 12.6% 291 (104/827) and 9.4% (60/636) had preterm birth. Statistically, vaccination also did not affect delivery 292 293 outcomes such as birth trauma (p=1), uterine rupture (p=1), unplanned ICU admission (p=0.1956), quantitative blood loss>1000mL (p=0.4452) or hemorrhage with transfusion (p=0.3531), mode of 294 delivery (p=0.6517), and stillbirth (p=1).¹⁹ 295
- 296 Neonatal outcomes

As many as 15% (2/13) required NICU admission, 8% (1/13) experienced TTN, and 8% (1/13) required supplemental oxygen or CPAP. Preterm delivery was reported in 8% (1/13) of women.¹¹ Moreover, 0.1% (1/725) were stillbirth, 3.2% (23/724) had small size for gestational age and 2.2% (16/724) had congenital anomalies. No neonatal death was reported.¹⁰ On statistical analysis, NICU admission (p=0.5821), 5 minute Apgar <7 (0.7617), hypoxic ischemic encephalopathy (p=1), and low birth weight (p= 0.5321) or very low birth weight (p= 0.2332), did not differ significantly between vaccinated and unvaccinated women.¹⁹

304 **DISCUSSION**

305 Main Finding

It has been described that Pfizer-BioNTech and Moderna vaccines were efficacious for preventing 306 future SARS-CoV-2 infection in pregnant women.¹⁹ Following Pfizer-BioNTech and Moderna 307 vaccinations, the vast majority of pregnant women will have injection-site pain or soreness.^{10,11,16} 308 309 Some most-experienced systemic adverse events were fatigue, headache, chills, myalgia, fever, and nausea.^{10,16} The incidence of these systemic adverse events were higher after the second dose 310 compared to the first dose.¹⁰⁻¹² Numerically, there were more individuals who experienced these 311 systemic adverse events in Moderna vaccine group than that of Pfizer-BioNTech group.¹⁰ The 312 313 adverse events were not statistically differ between pregnant and non pregnant women, except 314 seizure. However, the woman was known to have a history of seizure disorder and the anticonvulsant level was measured borderline-low.¹⁹ Interestingly, the pregnancy, delivery, and 315 neonatal outcomes did not differ between pregnant and non pregnant women.¹⁹ 316

Maternal antibody response has been described formed following vaccination.^{11-15,17,18,20} 317 Through vaccination, antibody response was formed rapidly; while through vaccination it was 318 formed gradually.²⁰ The number of IgG and IgM against SARS-CoV-2 were significantly increased 319 320 after vaccination. The response was increased after a booster was given.^{11,13} Although vast majority of pregnant women had IgG seroconversion, IgM seroconversions were observed in a minority of 321 pregnant women.¹⁸ After vaccination, IgG against S1, S2 and RBD formed whilst IgG against S1, 322 S2, RBD and N protein formed following natural infections. Moreover, S1- and RBD- IgG were 323 observed higher in vaccinated pregnant women. Meanwhile the S2- and N- IgG were observed 324 higher in naturally infected pregnant women.²⁰ Also, the RBD IgG and neutralizing antibody was 325 higher in vaccinated individuals than that of naturally infected.¹² 326

Antibody transfer was also reported.^{12,14,15,17,18,20,21} Cord blood antibody and maternal antibody levels were about equal.¹⁸ Additionally, latency and number of doses were correlated with the antibody transfer strength.^{14,18} The longer the latency, the better the antibody transfer and the higher
 the IgG.¹⁸ A mother who received two doses of vaccines would have her infant getting higher IgG
 levels.¹⁸ Between infection and vaccination, there was no difference in maternal-fetal IgG
 response.²⁰

333 Finding on other studies

A sufficient herd immunity threshold in a population will provide indirect protection for susceptible individuals from infected hosts.²² The threshold varies across different infections.²³⁻²⁵ In Covid-19, it was said that for a vaccine with 100% efficacy and providing life-long protection, we would need 60-75% herd immunity. This required number would be increased if the vaccine efficacy was reduced to 85%; a 75-90% herd immunity would be required.²⁶ Although we described that Pfizer-BioNTech and Moderna vaccines are efficacious to prevent future SARS-CoV-2 infection, whether the efficacy of these vaccines is reduced in pregnancy remains unknown.

This herd immunity threshold may also vary across populations. It depends on some factors-epidemiological factors (e.g., population density and transmission dynamics) and immunological factors (e.g., immune stats of population).²² An approach to achieve this threshold is through mass vaccination campaigns.²² Thus, high vaccination coverage is important for achieving sufficient herd immunity.^{27,28}

346 On note, not only pregnant individuals but also those who were not pregnant will experience 347 these adverse reactions as well. In Moderna and Pfizer-BioNTech studies where pregnant women and children were excluded, the incidence of systemic adverse events increased after the second 348 dose of vaccine.^{29,30} Following the Moderna vaccine booster, local pain was experienced by 83.2-349 89.9% of individuals, followed by fatigue (58.3-65.3%) and headache (46.2-62.8%). Meanwhile, 350 there were 10.0-15.5% who experienced fever. These were generally resolved within 3.1-3.2 days.²⁹ 351 Following the Pfizer-BioNTech vaccine booster, injection-site pain was experienced by 66%-78% 352 individuals, followed by fatigue (51-59%) and headache (39-52%). Meanwhile, fever was 353 experienced by 11-16% of individuals. These adverse events were transient, resolved within 1-2 354 days.30 355

356 Safety is an important concern for Covid-19 vaccination in pregnant women. Based on a survey 357 in 16 countries, pregnant women were less likely to accept vaccines for themselves. Given that a 358 Covid-19 vaccine had 90% efficacy, 73.4% non-pregnant women intended to receive the vaccine 359 while pregnant women were only 52%. The confidence in vaccine safety and effectiveness was one 360 of the predictors for vaccine acceptance.³¹ However, vaccination safety did not differ among those who are pregnant or not. Moreover, vaccination did not affect pregnancy, delivery, and pregnancy
 outcomes. On the other hand, some conditions during pregnancy made pregnant women susceptible
 to severe disease of Covid-19.³²

During pregnancy, the upper respiratory tract was swollen and lung expansion was restricted. It makes pregnant women more susceptible to respiratory pathogens.³³ Moreover, pro-inflammatory phase was present in the first trimester, for the implantation of the embryo and placenta, and third trimester, to prepare for the initiation of labor.³⁴ In fact, severe Covid-19 is associated with cytokine storms.³⁵ The pro-inflammatory phase during the first and third trimester of pregnancy, made them to be more prone to severe Covid-19.³⁶

Individuals with significant medical comorbidities, the elderly, and pregnant women are highly 370 vulnerable to Covid-19 infection.^{37,38} Although newborns and infants are less likely to get SARS-371 CoV-2 infections, they are more prone to severe SARS-CoV-2 infection.^{37,39,40} Passive immunity in 372 373 neonates may be potentially protective. Administration of booster doses can enhance antibody transfer which may provide a better immunity in neonates. However, this fetal passive immunity 374 may be altered due to placental sieving⁴¹, depending on the gestational age at first vaccine dose or 375 376 infection. The longer latency interval from first dose of vaccination to delivery should be required for better antibody transfer.¹⁸ 377

In contrast to natural viral infection such as in Zika dan DENV,^{42,43} antibody transfer observed following other vaccinations such as in pertussis and Influenza vaccines.^{44,45,46} Timeframe following natural SARS-CoV-2 infection may affect antibody transfer. An earlier Covid-19 infection may provide a better placental antibody transfer.²⁰ Additionally, poor placental antibody transfer was exclusively observed only in the third trimester of pregnancy, even though the maternal antibody response was significantly higher.⁴⁷ Natural infection may result in higher morbidity and mortality⁴⁸, so vaccination should be the better option for the dyads.

Many SARS-CoV-2 mutations had altered Covid-19 transmissibility and, probably, 385 severity.^{49,50,51} Moreover, these mutations can also impact a treatment efficacy, especially 386 monoclonal antibody treatments due to immune escape.^{52,53,54} It had been reported, compared to the 387 388 wild type of USA-WA1/2020 SARS-CoV-2, the binding strength of neutralizing antibodies formed after Pfizer and Moderna vaccination was observed 3.5- and 6- fold lower for B.1.1.7 and B.1351, 389 respectively.¹² Antibody resistance against B.1.1.7 and B.1351 was also reported by another study.⁵⁵ 390 In addition, in UK, it also was reported that B.1.617.2 had overtaken B.1.1.7. variants.⁵⁶ 391 Maximizing the second dose vaccine coverage may provide a stronger protection against this 392 variant.⁵⁷ However, we still need to know whether we would need a new vaccine or booster dose 393 394 since there are evidence of reduced efficacy of currently available vaccine for these strains. This problem should be taken more seriously, and other public health measures are necessary as an effort
 to end this pandemic.⁵⁸

397 Strength and limitation

To the best of our knowledge, this systematic review used the most recent evidence to describe the efficacy, safety and immunogenicity of Covid-19 mRNA vaccine in pregnancy. All studies included in this review were assessed as high quality studies. However, studies are all observational studies due to no RCTs reports of Covid-19 vaccination for pregnant women yet currently available. These studies reported only from mRNA type vaccines. Moreover, all available studies that were included were only from the United States and Israel.

404 CONCLUSION

In this study, mRNA vaccines, especially Pfizer-BioNTech and Moderna vaccines, are efficacious 405 406 for preventing future SARS-CoV-2 infections. These vaccines can induce antibody responses for 407 pregnant women and their fetus. Pregnant women should be given two doses of vaccine for more 408 robust maternal and fetal antibody response. Longer latency was associated with more robust fetal 409 antibody response. Almost all pregnant women who received vaccination, either in the first or 410 second dose, will experience injection-site pain. Furthermore, the second dose of vaccine will 411 produce more systemic adverse events than that of the first dose and administration of Moderna 412 vaccine was observed to have a more frequent systemic adverse events. Biologically speaking, we 413 may conclude that for a short term, vaccination did not affect pregnancy, delivery, or neonatal 414 outcomes.

415 **REFERENCES**

- Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019
 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020;222(6):521-531. doi:
 10.1016/j.ajog.2020.03.021.
- 419
 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395(10223):497–506. doi:
 10.1016/S0140-6736(20)30183-5.
- 3. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update:
 Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed
 SARS-CoV-2 Infection by Pregnancy Status United States, January 22-October 3,
 2020. MMWR Morb Mortal Wkly Rep 2020;69(44):1641-1647.
 doi:10.15585/mmwr.mm6944e3
- 4. Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. Coronavirus disease
 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol
 2021;26:S0002-9378(21)00187-3. doi: 10.1016/j.ajog.2021.03.023.
- 430 5. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women
 431 Admitted for Delivery. N Engl J Med. 2020;28;382(22):2163-2164. doi:
 432 10.1056/NEJMc2009316
- 433 6. Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. 434 Proportion of asymptomatic infection among COVID-19 positive persons and their 435 transmission potential: А systematic review and meta-analysis. PLoS One 2020;3;15(11):e0241536. doi: 10.1371/journal.pone.0241536. 436
- 7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ
 2021;372:n71. doi:10.1136/bmj.n71
- 8. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa
 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed
 June 27, 2021. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- 443 9. Joanna Briggs Institute. Checklist for systematic reviews and research syntheses. Accessed
 444 June 26, 2021. https://jbi.global/critical-appraisal-tools
- 10. Shimabukuro TT, Kim SY, Myers TR, Podo PL, Oduyebo T, Panagiotakopoulos L, et al.
 Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med
 2021;384(24):2273-2282. doi:10.1056/NEJMoa2104983

- 448 11. Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. Coronavirus disease
 449 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol,
 450 2021;S0002-9378(21)00187-3. doi:10.1016/j.ajog.2021.03.023
- 451 12. Collier AY, McMahan K, Yu J, Tostanoski LH, Aguayo R, Ansel J, et al. Immunogenicity of
 452 COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA 2021;325(23):2370453 2380. doi:10.1001/jama.2021.7563
- 13. Shanes ED, Otero S, Mithal LB, Mupanomunda CA, Miller ES, Goldstein JA. Severe Acute
 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy: Measures of
 Immunity and Placental Histopathology. Obstet Gynecol
 2021;10.1097/AOG.000000000004457. doi:10.1097/AOG.00000000004457
- 458 14. Prabhu M, Murphy EA, Sukhu AC, Yee J, Singh S, Eng D, et al. Antibody response to SARS459 CoV-2 mRNA vaccines in pregnant women and their neonates. bioRxiv (preprint)
 460 2021;2021.04.05.438524.
- 461 15. Gill L, Jones CW. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
 462 Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy. Obstet Gynecol
 463 2021;137(5):894-896. doi:10.1097/AOG.00000000004367
- 464 16. Kadali RAK, Janagama R, Peruru SR, Racherla S, Tirumala R, Madathala RR, et al. Adverse
 465 effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional
 466 study on healthcare workers with detailed self-reported symptoms. Am J Obstet Gynecol
 467 2021;10:S0002-9378(21)00638-4. doi:10.1016/j.ajog.2021.06.007
- 17. Rottenstreich A, Zarbiv G, Oiknine-Djian E, Zigron R, Wolf DG, Porat S. Efficient
 maternofetal transplacental transfer of anti- SARS-CoV-2 spike antibodies after antenatal
 SARS-CoV-2 BNT162b2 mRNA vaccination. Clin Infect Dis 2021;3:ciab266.
 doi:10.1093/cid/ciab266
- 472 18. Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following
 473 maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol
 474 2021;1:S0002-9378(21)00215-5. doi:10.1016/j.ajog.2021.03.035
- 475 19. Theiler RN, Wick M, Mehta R, Weaver A, Virk A, Swift M. Pregnancy and birth outcomes
 476 after SARS-CoV-2 vaccination in pregnancy. medRxiv (preprint) 2021;2021.05.17.21257337.
- 20. Beharier O, Plitman Mayo R, Raz T, Nahum Sacks K, Schreiber L, Suissa-Cohen Y, et al.
 Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2
 mRNA COVID-19 vaccine. J Clin Invest 2021;150319. doi:10.1172/JCI150319
- 480 21. Paul G, Chad R. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal
 481 vaccination a case report. BMC Pediatr 2021;21:138. doi: 10.1186/s12887-021-02618-y

- 482 22. Randolph H, Barreiro L. Herd Immunity: Understanding COVID-19. Immunity
 483 2020;52(5):737-741. doi:10.1016/j.immuni.2020.04.012
- Vignesh R, Shankar E, Velu V, Thyagarajan S. Is Herd Immunity Against SARS-CoV-2 a
 Silver Lining ?. Frontiers In Immunology 2020;11:586781. doi: 10.3389/fimmu.2020.586781
- 486 24. Xia Y, Zhong L, Tan J, Zhang Z, Lyu J, Chen Y, et al. How to Understand "Herd Immunity" in
 487 COVID-19 Pandemic. Frontiers In Cell And Developmental Biology 2020;8:547314. doi:
 488 10.3389/fcell.2020.547314
- 489 25. Griffith B, Ulrich A, Becker A, Nederhoff D, Koch B, Awan F, et al. Does education about
 490 local vaccination rates and the importance of herd immunity change US parents' concern about
 491 measles?. Vaccine 2020;38(50), 8040-8048. doi:10.1016/j.vaccine.2020.09.076
- 492 26. Anderson R, Vegvari C, Truscott J, Collyer B. Challenges in creating herd immunity to SARS493 CoV-2 infection by mass vaccination. The Lancet 2020;396(10263):1614-1616. doi:
 494 10.1016/S0140-6736(20)32318-7
- 495 27. Lahariya C. Vaccine epidemiology: A review. Journal Of Family Medicine And Primary Care
 496 2016;5(1):7. doi: 10.4103/2249-4863.184616
- 497 28. Orenstein W, Seib K. Mounting a Good Offense against Measles. New England Journal Of
 498 Medicine 2014;371(18):1661-1663. doi: 10.1056/NEJMp1408696
- 29. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of
 the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal Of Medicine 2021;384(5):403416. doi: 10.1056/NEJMoa2035389
- 502 30. Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy
 503 of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal Of Medicine
 504 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- 505 31. Skjefte M, Ngirbabul M, Akeju O, Escudero D, Hernandez-Diaz S, Wyszynski D, et al.
 506 COVID-19 vaccine acceptance among pregnant women and mothers of young children: results
 507 of a survey in 16 countries. European Journal Of Epidemiology 2021;36(2):197-211.
 508 doi:10.1007/s10654-021-00728-6
- 32. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations,
 risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy:
 living systematic review and meta-analysis. BMJ 2020;370:m3320. doi: 10.1136/bmj.m3320
- 512 33. Cavalcante MB, Cavalcante CTMB, Sarno M, Barini R, Kwak-Kim J. Maternal immune
 513 responses and obstetrical outcomes of pregnant women with COVID-19 and possible health
 514 risks of offspring. J Reprod Immunol 2021;2;143:103250. doi: 10.1016/j.jri.2020.103250

- 515 34. Mor G. The unique immunological and microbial aspects of pregnancy. Nat. Rev. Immunol
 516 2017;17:469–482. doi: 10.1038/nri.2017.64
- 517 35. Huang C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
 518 Lancet 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5
- 36. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update:
 Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed
 SARS-CoV-2 Infection by Pregnancy Status United States, January 22-October 3, 2020.
 MMWR Morb Mortal Wkly Rep 2020;6;69(44):1641-1647. doi: 10.15585/mmwr.mm6944e3.
- 37. Levin A, Hanage W, Owusu-Boaitey N, Cochran K, Walsh S, Meyerowitz-Katz G. Assessing
 the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis,
 and public policy implications. European Journal Of Epidemiology 2020;35(12), 1123-1138.
 doi: 10.1007/s10654-020-00698-1
- 38. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID19 cases: A systematic literature review and meta-analysis. Journal Of Infection
 2020;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021.
- 39. Liguoro I, Pilotto C, Bonanni M, Ferrari M, Pusiol A, Nocerino A, et al. SARS-COV-2
 infection in children and newborns: a systematic review. European Journal Of Pediatrics
 2020;179(7):1029-1046. doi: 10.1007/s00431-020-03684-7
- 40. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among
 Children in China. Pediatrics 2020;145(6):e20200702. doi:10.1542/peds.2020-0702
- 41. Jennewein M, Goldfarb I, Dolatshahi S, Cosgrove C, Noelette F, Krykbaeva M, et al. Fc
 Glycan-Mediated Regulation of Placental Antibody Transfer. Cell 2019;178(1), 202-215.e14.
 doi: 10.1016/j.cell.2019.05.044
- 42. Atyeo C, Pullen K, Bordt E, Fischinger S, Burke J, Michell A, et al. Compromised SARSCoV-2-specific placental antibody transfer. Cell 2021;184(3):628-642.e10. doi:
 10.1016/j.cell.2020.12.027
- 43. Haghpanah F, Lin G, Levin S, Klein E. Analysis of the potential impact of durability, timing,
 and transmission blocking of COVID-19 vaccine on morbidity and mortality.
 Eclinicalmedicine 2021;35;100863. doi: 10.1016/j.eclinm.2021.100863
- 44. Castanha PMS, Souza WV, Braga C, Araújo TVB, Ximenes RAA, Albuquerque MFPM, et al.
 Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly
 case-control study in an area of high dengue endemicity in Brazil. PLoS Negl Trop Dis
 2019;11;13(3):e0007246. doi: 10.1371/journal.pntd.0007246.

- 548 45. Perret C, Chanthavanich P, Pengsaa K, Limkittikul K, Hutajaroen P, Bunn JE, et al. Dengue
 549 infection during pregnancy and transplacental antibody transfer in Thai mothers. J Infect
 550 2005;51(4):287-93. doi: 10.1016/j.jinf.2004.10.003.
- 46. Gonçalves G, Cutts FT, Hills M, Rebelo-Andrade H, Trigo FA, Barros H. Transplacental
 transfer of measles and total IgG. Epidemiol Infect 1999;122(2):273-9. doi:
 10.1017/s0950268899002046.
- 47. Heininger U, Riffelmann M, Leineweber B, Wirsing von Koenig CH. Maternally derived
 antibodies against Bordetella pertussis antigens pertussis toxin and filamentous hemagglutinin
 in preterm and full term newborns. Pediatr Infect Dis J 2009;28(5):443-5. doi:
 10.1097/INF.0b013e318193ead7.
- 48. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and
 immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during
 pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014;7;311(17):1760-9.
 doi: 10.1001/jama.2014.3633.
- 49. Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W et al. Tracking Changes
 in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
 Cell. 2020;182(4):812-827.e19. doi: 10.1016/j.cell.2020.06.043
- 50. Bian L, Gao F, Zhang J, He Q, Mao Q, Xu M et al. Effects of SARS-CoV-2 variants on
 vaccine efficacy and response strategies. Expert Review of Vaccines. 2021;:1-9. doi:
 10.1080/14760584.2021.1903879
- 568 51. Gómez C, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in Global
 569 Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines. 2021;9(3):243. doi:
 570 10.3390/vaccines9030243
- 52. Boehm E, Kronig I, Neher R, Eckerle I, Vetter P, Kaiser L. Novel SARS-CoV-2 variants: the
 pandemics within the pandemic. Clinical Microbiology and Infection. 2021. doi:
 10.1016/j.cmi.2021.05.022
- 574 53. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich B, Hahn A et al. SARS-CoV-2 variants
 575 B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184(9):2384-2393.e12. doi:
 576 10.1016/j.cell.2021.03.036. doi: 10.1016/j.cell.2021.03.036
- 54. Starr T, Greaney A, Dingens A, Bloom J. Complete map of SARS-CoV-2 RBD mutations that
 escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Reports
 Medicine. 2021;2(4):100255. doi: 10.1016/j.xcrm.2021.100255
- 55. Wang P, Nair M, Liu L, Iketani S, Luo Y, Guo Y et al. Antibody Resistance of SARS-CoV-2
 Variants B.1.351 and B.1.1.7. 2021. doi: 10.1101/2021.01.25.428137

- 56. Torjesen I. Covid-19: Delta variant is now UK's most dominant strain and spreading through
 schools. BMJ 2021;373:n1445. doi:10.1136/bmj.n144. doi: 10.1136/bmj.n144
- 57. Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S et al. Effectiveness of
 COVID-19 vaccines against the B.1.617.2 variant. 2021. doi:
 https://doi.org/10.1101/2021.05.22.21257658
- 587 58. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj S, Ghammam R et al. Effective public
- health measures to mitigate the spread of COVID-19: a systematic review. BMC Public Health.
- 5892021;21(1). doi: 10.1186/s12889-021-11111-1